TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26160880
Drug: Panobinostat monotherapy
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panobinostat monotherapy during maintenance phase for patients with persistent minimal residual disease.
Study: 26161450
Drug: TNFα soluble
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TNFα soluble receptors 1 (TNFα-sR1)
Study: 26161450
Drug: TNFα soluble
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TNFα soluble receptors 2 (TNFα-sR2)
Study: 26161618
Drug: AXL1717, 390
Approvals — FDA: no, EMA: no, PMDA: no
Description: AXL1717, 390 mg BID for four weeks (RP2D)
Study: 26163041
Drug: Early clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early clopidogrel therapy (initiation within 24 hours of hospital admission)
Study: 26163041
Drug: Early clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early clopidogrel therapy
Study: 26163041
Drug: Early clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early clopidogrel therapy in urban hospitals
Study: 26163041
Drug: Early clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early clopidogrel therapy in rural hospitals
Study: 26168005
Drug: Antibiotic prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prescriptions resulting from influenza-attributable GP episodes
Study: 26170136
Drug: Ombitasvir (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ombitasvir (25 mg), Paritaprevir (150 mg), and Ritonavir (100 mg) once daily for 12 weeks (without cirrhosis) or 24 weeks (with cirrhosis)
Study: 26171276
Drug: V1512 (melevodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: V1512 (melevodopa 100 mg/carbidopa 25 mg)
Study: 26171276
Drug: L-dopa 100
Normalized name: L-DOPA 100 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa 100 mg/carbidopa 25 mg
Study: 26171276
Drug: V1512 or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: V1512 or L-dopa/carbidopa in combination with entacapone 200 mg
Study: 26172064
Drug: Instrumental activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instrumental activities of daily living
Study: 26172205
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal mitomycin C (PL-MLP) at doses of 0.5-3.5 mg/kg every 4 weeks for up to 12 cycles
Study: 26175532
Drug: Referral to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral to geriatrics or physical/occupational therapy
Study: 26176325
Drug: K+D group
Normalized name: Effer-K
Approvals — FDA: no, EMA: no, PMDA: no
Description: K+D group (90 μg of vitamin K2 and 10 μg of cholecalciferol)
Study: 26176325
Drug: D group
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: D group (10 μg of cholecalciferol)
Study: 26176329
Drug: Anti-SAP antibody
Normalized name: Bambusa vulgaris sap extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-SAP antibody infusion after CPHPC treatment
Study: 26176329
Drug: CPHPC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPHPC treatment
Study: 26176329
Drug: Anti-SAP antibody
Normalized name: Bambusa vulgaris sap extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-SAP antibody infusion
Study: 26176493
Drug: Low vitamin
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low vitamin D levels (<30 ng/ml)
Study: 26176493
Drug: Normal vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal vitamin D levels (≥30 ng/ml)
Study: 26176696
Drug: Lead-in therapy
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lead-in therapy with intravenous silibinin 20 mg/kg/day for 14 days followed by triple-therapy (peginterferon-ribavirin and telaprevir) for 12 weeks, and peginterferon-ribavirin alone for 36 weeks.
Study: 26176696
Drug: Lead-in therapy
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lead-in therapy with intravenous silibinin
Study: 26178526
Drug: Sildenafil 100
Normalized name: sildenafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 100 mg/d for 3 months
Study: 26178723
Drug: 25-hydroxyvitamin D
Normalized name: 25-hydroxyvitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-hydroxyvitamin D concentrations <50 nmol/L
Study: 26179200
Drug: Emactuzumab 900
Normalized name: Emactuzumab
DrugBank: Emactuzumab (DB14905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emactuzumab 900 mg, 1350 mg, or 2000 mg every 2 weeks (dose-escalation phase) and 1000 mg every 2 weeks (dose-expansion phase)
Study: 26180085
Drug: ASK1 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASK1 inhibitor (GS-444217 delivered in chow) - early intervention (2-8 weeks after STZ)
Study: 26180085
Drug: ASK1 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASK1 inhibitor (GS-444217 delivered in chow) - late intervention (weeks 8-15 after STZ)
Study: 26181029
Drug: Erlotinib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib monotherapy for 13 days
Study: 26181354
Drug: T790M-specific EGFR
Normalized name: PACIFIC OYSTER
Approvals — FDA: no, EMA: no, PMDA: no
Description: T790M-specific EGFR inhibitor
Study: 26183044
Drug: Neoadjuvant drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant drug therapy with oxaliplatin and capecitabine (and panitumumab for patients without KRAS, BRAF, and PIK3CA mutations)
Study: 26183076
Drug: Nonmyeloablative related-donor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonmyeloablative related-donor allo-BMT with post-transplantation rituximab and high-dose post-transplantation cyclophosphamide (PTCy)
Study: 26185466
Drug: Extended-release morphine
Normalized name: morphine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release morphine sulfate with sequestered naltrexone hydrochloride (MSN)
Study: 26185773
Drug: MOR103 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOR103 0.5 mg/kg
Study: 26185773
Drug: MOR103 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOR103 2.0 mg/kg
Study: 26186012
Drug: Bevacizumab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (5 mg/kg every two weeks or 7.5 mg/kg every three weeks) combined with modified FOLFOX6 (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-FU 400 mg/m2 on day 1, followed by 5-FU 2400 mg/m2 intravenous infusion over 46 hours every 2 weeks)
Study: 26186135
Drug: Urinary inorganic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary inorganic arsenic plus methylated species (∑As) (µg/L) during pregnancy
Study: 26186440
Drug: ART plus
Normalized name: Tri-Heart Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART plus low doses of IL-2
Study: 26186556
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy using docetaxel, cisplatin, and fluorouracil (TPF)
Study: 26187031
Drug: Ledipasvir and
Normalized name: Ledipasvir and Sofosbuvir Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir and sofosbuvir treatment
Study: 26187300
Drug: Corifollitropin alfa
Normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Corifollitropin alfa (150 μg single injection for 7 days, followed by daily recombinant FSH/hMG)
Study: 26187510
Drug: (90)Y-clivatuzumab tetraxetan
Normalized name: tetraxetan
Approvals — FDA: no, EMA: no, PMDA: no
Description: (90)Y-clivatuzumab tetraxetan plus low-dose gemcitabine (Arm A)
Study: 26190562
Drug: Allopurinol <
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol < 300 mg
Study: 26190562
Drug: Allopurinol >
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol > 300 mg
Study: 26194541
Drug: Baked milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baked milk oral immunotherapy (BM OIT) with a dose of 1.3 g/d BM protein, increased 50% monthly under medical supervision.
Study: 26194541
Drug: Baked milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baked milk oral immunotherapy (BM OIT)
Study: 26195184
Drug: Liraglutide 0.6
Normalized name: liraglutide 0.6 mg/0.1 mL (18 mg/3 mL) SUBCUT PEN INJECTOR (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 0.6 mg/day for 2 weeks, followed by 1.2 mg/day, in addition to metformin
Study: 26195220
Drug: Endothelial nitric
Normalized name: nitric oxide synthase endothelial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelial nitric oxide synthase-transfected endothelial progenitor cells (7 to 50 million cells, divided into 3 doses on consecutive days)
Study: 26195720
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (1.8 mg/kg) every 3 weeks for a maximum of sixteen doses
Study: 26196225
Drug: Ambrisentan (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan (5 or 10 mg once daily)
Study: 26196225
Drug: Ambrisentan and
Normalized name: ambrisentan and tadalafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan and tadalafil (upfront initial combination therapy)
Study: 26196233
Drug: AMH (Antimüllerian
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMH (Antimüllerian hormone)
Study: 26197243
Drug: Energy-restricted treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy-restricted treatment (hypocaloric diet)
Study: 26199039
Drug: Ridaforolimus 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ridaforolimus 20 mg daily (5 days/week) + MK-0752 1800 mg weekly
Study: 26199039
Drug: Ridaforolimus 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ridaforolimus 30 mg daily (5 days/week) + MK-0752 1800 mg weekly
Study: 26199392
Drug: Sequential high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential high-dose chemotherapy (HDC) with bevacizumab preceding GemDMC (cycle 1) and ICE (cycle 2)
Study: 26199453
Drug: Adalimumab (ADA)
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab (ADA) 40 mg every other week or monthly
Study: 26201460
Drug: Ranibizumab injections
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab injections (3 injections)
Study: 26201817
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg pyridoxine hydrochloric acid/d for 28 days
Study: 26203353
Drug: Goal-directed fluid
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed fluid therapy (GDFT) with arterial-based continuous stroke volume variation (SVV) monitoring
Study: 26203353
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard fluid therapy)
Study: 26205955
Drug: Short-course neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course neoadjuvant chemotherapy (NACT) followed by long-course chemoradiotherapy and definitive surgery, with a focus on the increase in circulating carbonic anhydrase IX (CAIX) levels above a threshold of 224 pg/ml after NACT.
Study: 26210442
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of busulfan over 90 hours
Study: 26210442
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of busulfan with intermittent fludarabine
Study: 26210512
Drug: Probiotic therapy
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic therapy for four weeks in addition to standard of care
Study: 26210682
Drug: RG7112 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7112 with new formulation under fasting condition
Study: 26210682
Drug: RG7112 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7112 with multiple-dose administrations (4 schedules)
Study: 26210682
Drug: High-dose consecutive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose consecutive daily dosing for 5 days
Study: 26210682
Drug: High-dose consecutive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose consecutive daily dosing for 3 days
Study: 26210682
Drug: Weekly dosing
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly dosing schedule
Study: 26210682
Drug: Low-dose/long-duration (20-day)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose/long-duration (20-day) daily schedule
Study: 26211987
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (1.8 mg/kg) administered i.v. on day 1 of a 21-day cycle for a total of 4 cycles
Study: 26212068
Drug: DNA methylation
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA methylation and histone deacetylase inhibitors
Study: 26213141
Drug: MK2206 (AKT
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK2206 (AKT inhibitor) administered orally at 200 mg once weekly in 28-day cycles up to 12 cycles; final doses included 300 mg (n=33), 250 mg (n=2), 200 mg (n=16), and 135 mg (n=8).
Study: 26213141
Drug: MK2206 (AKT
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK2206 (AKT inhibitor)
Study: 26213309
Drug: CRP level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP level of ≤10 mg/liter and MBDA score of >44
Study: 26213309
Drug: CRP level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP level of >10 mg/liter
Study: 26213608
Drug: Subcutaneous specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous specific immunotherapy (SCIT) with a standardized allergen extract from Olea europaea; up-dosing doses: 300, 600, 3000, 6000, and 15000SQ+ administered weekly, followed by a maintenance dose of 15000SQ+ after 2 weeks
Study: 26217225
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (SNP) at doses of 0.3, 1, 2, or 3 μg/kg/min infused for 30 min followed by open-label administration for at least 90 min.
Study: 26217540
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus polyglucosamine (ST + PG)
Study: 26217540
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus placebo (ST + PL)
Study: 26218032
Drug: Weekly prophylaxis
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly prophylaxis
Study: 26218032
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no inhibitors observed)
Study: 26218540
Drug: AZD8329 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8329 (single oral doses or repeat daily doses for 7-9 days)
Study: 26218540
Drug: COMPOUND-20 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: COMPOUND-20 (single oral doses or repeat daily doses for 7-9 days)
Study: 26218540
Drug: COMPOUND-20 (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: COMPOUND-20 (continuous cover for 7 days)
Study: 26221138
Drug: Subantimicrobial dose
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subantimicrobial dose doxycycline (50 mg/d) for 12 weeks
Study: 26222441
Drug: Subgam (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgam (normal immunoglobulin, IgG) given weekly as a rapid subcutaneous infusion
Study: 26222558
Drug: PLX3397 (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLX3397 (1000 mg per day)
Study: 26223436
Drug: MEDI-575 9
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-575 9 mg/kg/week
Study: 26223436
Drug: MEDI-575 15
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-575 15 mg/kg/week
Study: 26223436
Drug: MEDI-575 35
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-575 35 mg/kg/3-weekly
Study: 26223436
Drug: MEDI-575 25
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-575 25 mg/kg/3-weekly
Study: 26224101
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g of parmesan cheese, a boiled egg and 300 ml of water
Study: 26227196
Drug: Emerging disease-modifying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emerging disease-modifying treatments for aortic stenosis
Study: 26228486
Drug: 0.03% and
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% and 0.06% topical resiquimod gel
Study: 26228971
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam radiotherapy (conformal 3D planning or intensity modulated radiotherapy) to a cumulative dose of approximately 40 Gy; systemic therapy maintained unaltered.
Study: 26235450
Drug: Oral anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulants (including vitamin K antagonists and non-vitamin K oral anticoagulants)
Study: 26235450
Drug: Oral anticoagulant-associated
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant-associated intracerebral hemorrhage
Study: 26235848
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (n=48)
Study: 26236506
Drug: Interferon β-1a
Normalized name: Interferon beta 1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon β-1a 44 μg or 22 μg subcutaneously three times weekly
Study: 26239690
Drug: Concurrent antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent antipsychotic medications (including 40 mg pimavanserin daily)
Study: 26239690
Drug: Concurrent antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent antipsychotic medications
Study: 26242184
Drug: GLP-1RA therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GLP-1RA therapy
Study: 26242794
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of depression as measured by the Montgomery and Asberg Depression Rating Scale (MADRS)
Study: 26242794
Drug: Individual MADRS
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual MADRS items during treatment
Study: 26242981
Drug: Intravenous adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous adenosine infusion (140-175mcg/kg/min)
Study: 26242981
Drug: Regadenoson single-bolus
Normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regadenoson single-bolus administration
Study: 26244832
Drug: Dolutegravir (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir (1.0 mg/kg once daily)
Study: 26245196
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 10 µL with 2,500 PfSPZ (n=6)
Study: 26245196
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 50 µL with 2,500 PfSPZ (n=6)
Study: 26245196
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 250 µL with 2,500 PfSPZ (n=6)
Study: 26245196
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 25,000 PfSPZ (n=6)
Study: 26245196
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 75,000 PfSPZ (n=6)
Study: 26248353
Drug: 1g meropenem
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1g meropenem every 8 hours as a 15-min infusion
Study: 26248638
Drug: secukinumab 2×10
Approvals — FDA: no, EMA: no, PMDA: no
Description: secukinumab 2×10 mg/kg intravenously followed by 3 mg/kg IV every 4 weeks
Study: 26250067
Drug: Brexpiprazole (2-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brexpiprazole (2-4 mg/day for schizophrenia)
Study: 26250067
Drug: Brexpiprazole (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brexpiprazole (1, 2, and 3 mg for MDD)
Study: 26251214
Drug: Mock treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mock treatment with a control peptide
Study: 26251251
Drug: SAMMPRIS medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAMMPRIS medical treatment
Study: 26251251
Drug: WASID treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: WASID treatment
Study: 26252393
Drug: Migalastat HCl
Normalized name: migalastat HCl
DrugBank: Migalastat (DB05018)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Migalastat HCl (150 mg or 450 mg) co-administered with agalsidase (0.2, 0.5, or 1.0 mg/kg)
Study: 26252393
Drug: Agalsidase (0.2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agalsidase (0.2, 0.5, or 1.0 mg/kg) alone
Study: 26254174
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor (letrozol, 2.5 mg/d for 3 months)
Study: 28692407
Drug: Medication-assisted treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-assisted treatment (MAT)
Study: 26254317
Drug: Drug-free counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free counseling
Study: 26254317
Drug: Residential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residential treatment preference
Study: 26254445
Drug: Hospital level
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital level variation in treatment
Study: 26254812
Drug: MET-HIT2000AB4 sandwich
Normalized name: Met
DrugBank: Methionine (DB00134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MET-HIT2000AB4 sandwich strategy (postoperative chemotherapy, hyperfractionated craniospinal radiotherapy, and maintenance chemotherapy)